To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
ClinicalTrials.gov · NCT01725126 · Registry updated: 2017-12-13
- Condition / research focus
- Obesity
- Sponsor
- GlaxoSmithKline
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2013-02-10. Completion: 2013-09-12 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- GSK2890457 (drug)
- Metformin (drug)
- Placebo (drug)
- Liraglutide (drug) — also listed as: Victoza
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- GSK Investigational SiteChula Vista, California, United States